Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31. But analysts are convinced ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. The New York-based company disclosed plans ...

In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...